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Aldehyde oxidases (AOXs) are a small group of enzymes
belonging to the larger family of molybdo-flavoenzymes, along
with the well-characterized xanthine oxidoreductase. The two
major types of reactions that are catalyzed by AOXs are the hy-
droxylation of heterocycles and the oxidation of aldehydes to
their corresponding carboxylic acids. Different animal species
have different complements of AOX genes. The two extremes
are represented in humans and rodents; whereas the human
genome contains a single active gene (AOX1), those of rodents,
such as mice, are endowed with four genes (Aox1-4), clustering
on the same chromosome, each encoding a functionally distinct
AOX enzyme. It still remains enigmatic why some species have
numerous AOX enzymes, whereas others harbor only one func-
tional enzyme. At present, little is known about the physiologi-
cal relevance of AOX enzymes in humans and their additional
forms in other mammals. These enzymes are expressed in the
liver and play an important role in the metabolisms of drugs and
other xenobiotics. In this review, we discuss the expression, tis-
sue-specific roles, and substrate specificities of the different
mammalian AOX enzymes and highlight insights into their
physiological roles.
Mammalian aldehyde oxidases (AOXs)2 are metal-contain-
ing enzymes that require the molybdenum cofactor (Moco),
two [2Fe-2S] clusters, and FAD for their catalytic activity (1, 2).
AOXs belong to the xanthine oxidase family of Moco-contain-
ing enzymes along with xanthine oxidoreductase (XOR), bac-
terial carbon monoxide dehydrogenases, periplasmic aldehyde
oxidoreductases, and other molybdoenzymes from pro-
karyotes. Humans contain a total of four molybdoenzymes,
namely aldehyde oxidase 1 (AOX1) (3), xanthine oxidoreduc-
tase (4), sulfite oxidase (5), and the mitochondrial amidoxime-
reducing component (6). In humans, the only essential molyb-
doenzyme is sulfite oxidase (7–9).
Eukaryotic AOXs are cytosolic proteins that are expressed in
many tissues of various organisms, including insects, rodents,
and humans (10, 11). AOXs oxidize purines, pyrimidines, and
pteridines and are involved in nicotinic acid metabolism (12). In
addition, AOXs bio-transform organic aldehydes into the cor-
responding carboxylic acids, hydroxylate heteroaromatic rings,
and catalyze the reduction of nitro- and sulfo-groups (13–18).
Given this broad substrate specificity, human AOX1 is an
emerging enzyme in the context of drug metabolism (19, 20).
Indeed, the number of drug molecules recognized and metab-
olized by AOXs is increasing, and this has raised the interest of
pharmaceutical companies (21, 22).
Despite these many characterized activities, the physiologi-
cal role of mammalian AOXs, is still a matter of debate (23). The
genomes of many prokaryotic and eukaryotic organisms con-
tain genes coding for AOX enzymes (11). In mammals, the
complement of AOX genes varies according to the animal spe-
cies considered (10, 11, 24). Mice and rats are characterized by
the largest number of active AOX genes (Aox1, Aox2, Aox3, and
Aox4),3 each coding for a different AOX enzyme (Fig. 1) (11). In
contrast, humans and the majority of primates contain a single
active AOX gene, which is the mAox1 orthologue (10). The
multiplicity of AOX genes observed in many vertebrates is the
result of a series of duplication events from a common ances-
tor gene. In the mammalian species characterized by multi-
ple AOX genes, the loci cluster on a short region of the same
chromosome.
The reason why mammals other than humans express
multiple AOX enzymes is unknown (25). Nevertheless, the
decrease in the number of active AOX isoenzymes from
rodents to humans is the result of progressive deletion/inacti-
vation of the corresponding genes (24). It can be speculated that
AOX2, AOX3, and AOX4 exert tissue-specific functions in
rodents, which are dispensable in humans. The physiological
role and demand for several AOX enzymes in certain organisms
may find an answer following definition of the physiological
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function and substrate specificity of the various mammalian
AOXs.
In this review, we discuss the evolution, expression, substrate
specificities, and structures of the different mammalian AOX
enzymes. The major aim is to give an overview on what is
known about the potential roles of these different enzyme
forms with a focus on the four enzymes present in mice. First
insights into the physiological role of one specific enzyme form
could be drawn from the physiological studies of mAox4/
knockout mice. Further, the role of reactive oxygen species
(ROS) production by AOX enzymes is discussed, because they
were produced in much higher proportions than previously
appreciated. For the role of human AOX1 in drug metabolism,
the reader is referred to numerous specialized reviews in the
literature covering this topic (12, 20, 25–28).
Domain structure and catalytic mechanism of the AOX
enzymes
AOX enzymes are present in both eukaryotes and pro-
karyotes. A common catalytic mechanism has been proposed
for all AOXs. Before we focus on the different AOX enzymes
present in mammals, we introduce the differences and com-
mon principles in the primary structures of AOX enzymes in
different organisms. AOXs in general are Moco-containing
enzymes that, with some exceptions in prokaryotes, contain
two [2Fe-2S] clusters and FAD as additional prosthetic groups.
First, it is important to give a brief overview on the structural
characteristics of prokaryotic AOX enzymes to highlight the
differences from and similarities with the eukaryotic counter-
parts. In bacteria and archaea, the xanthine oxidase family of
molybdoenzymes is complex, as it includes CO dehydrogenases
(29), aldehyde oxidoreductases (30 –32), and quinoline-meta-
bolizing (31) and nicotinic acid–metabolizing (33) enzymes. In
particular, the domain structure, the subunit composition, and
the cofactor complement of prokaryotic AOXs is variable (Fig.
2) (30 –32). Rhodobacter capsulatus/Veillonella atypica xan-
thine dehydrogenase (XDH) (34), Desulfovibrio gigas aldehyde
oxidoreductase (MOP) (30), and Escherichia coli periplasmic
aldehyde oxidoreductase (PaoABC) (35) are the enzymes show-
ing the highest structural similarities with eukaryotic xanthine
oxidoreductases and AOXs. The redox-active centers of the
bacterial and archaeal members of the xanthine oxidase family
are contained in separate subunits, and exceptions to the gen-
eral cofactor composition have also been identified (Fig. 2).
R. capsulatus XDH is organized as an ()2 heterodimer, and it
contains the eukaryotic form of Moco (assigned as Mo-molyb-
dopterin (Mo-MPT), Fig. 3). In contrast, V. atypica XDH con-
sists of an -heterotrimer, and it contains the MPT cytosine
dinucleotide (MCD) form of Moco (Fig. 3). In addition, MOP
lacks the FAD domain, and it consists of two identical subunits
organized as an 2 dimer (30). Each subunit contains the two
[2Fe-2S] clusters and the MCD cofactor. Finally, the periplas-
mic aldehyde oxidoreductase from E. coli is characterized by a
structure consisting of an -heterotrimer, which exception-
ally includes an additional [4Fe-4S] cluster proximal to the FAD
in the -subunit (35).
In comparison, the xanthine oxidase family of eukaryotic
molybdoenzymes consists solely of AOXs (EC 1.2.3.1) and
XORs. Two interconvertible forms of the mammalian XOR
enzyme are known, xanthine oxidase (XO; EC 1.17.3.2) and
XDH (EC 1.17.1.4). The domain structure of eukaryotic AOXs
is highly conserved, and the catalytically active enzymes are
organized as 2 homodimers (Fig. 2) (36, 37). Each subunit of
the catalytically active AOX and XOR homodimer contains
three cofactor-binding domains. The N-terminal domain binds
two [2Fe-2S] clusters known as FeSI and FeSII. The central
domain contains the FAD binding site, whereas the C-terminal
domain (4, 38–41) harbors the Moco in the Mo-MPT form (Fig.
3). The three domains are connected by flexible linker regions.
The characteristic of the molybdoenzymes belonging to the
xanthine oxidase family is the presence of an essential sulfur
atom acting as an equatorial sulfido ligand to the molybdenum
atom (MoS, Fig. 3) (42–45). The presence of this MoS
ligand is at the basis of the cyanide-dependent inactivation of
these molybdoenzymes (46). Cyanide treatment results in the
formation of an inactive desulfo form, and these enzymes can
be reversibly reactivated by treatment with sulfide and dithio-
nite (42, 43).
The major structural differences among the members of the
eukaryotic xanthine oxidase family are observed at the FAD site
(3, 38). These differences are particularly evident between the
FAD sites of AOXs and XORs, which react with the terminal
electron acceptor. The final electron acceptor is molecular oxy-
gen in the case of AOXs and XO, whereas it is NAD in the case
of XDH (47). The enzymes can be reversibly converted from the
XDH form to the XO form, which has been shown to involve
the formation of a new disulfide bond, between two cysteine
Figure 1. Organization of the human, mouse, and rat AOX genes. Shown is a schematic representation of the Homo sapiens, Mus musculus, and Rattus
norvegicus AOX genes and pseudogenes. Pseudogenes are marked by an asterisk.
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residues at the FAD site (Cys535 and Cys992 in bovine XOR). In
addition, the conversion of XDH into XO requires a structural
rearrangement of the 11-residue loop (Gln423–Lys433 in bovine
XOR) located in close proximity to the FAD cofactor (4). In
addition, the movement of this loop leads to a change in the
electrostatic environment around the FAD cofactor (48) and
Figure 2. Overview of the subunit composition and cofactor organization of aldehyde oxidases and xanthine oxidoreductases. In eukaryotes, the
catalytically active forms of AOXs and XORs consist of 2 homodimers. Each subunit of the dimer consists of separate domains containing the Moco catalytic
site, two distinct [2Fe-2S] redox centers, and the FAD-binding site. In the prokaryotic enzymes, the [2Fe-2S] cluster-binding subunits are shown in orange, the
subunits binding the FAD cofactor are colored in green, and the subunits containing the Moco are colored in blue. The FAD domain is absent in the D. gigas
aldehyde oxidoreductase. In the R. capsulatus xanthine dehydrogenase, the iron-sulfur and flavin-binding domains of the protein constitute one subunit
(XdhA), and the Mo-MPT– binding domain constitutes a second (XdhB) subunit. In the V. atypica xanthine dehydrogenase, the iron-sulfur centers are located
in one subunit (XdhA), the flavin in a second (XdhB), and the Moco as MCD in a third (XdhC) subunit. In the PaoABC from E. coli, a [4Fe-4S] cluster is present in
proximity to the FAD cofactor on the PaoB subunit. Potential substrates and electron acceptors are indicated.
Figure 3. Forms of the molybdenum cofactor present in enzymes of the xanthine oxidase family. Characteristic to enzymes of the xanthine oxidase family
is a sulfido ligand at the equatorial position of the molybdenum atom. In eukaryotic enzymes of this family, the basic form of Moco is a pyranopterin, named
Mo-MPT, which coordinates the molybdenum atom (colored in red) by the characteristic dithiolene group (colored in green) at the C1 and C2 positions of the
pyranopterin ring (colored in blue). In bacteria, the MPT core can be modified by an additional CMP nucleotide (colored in orange) at the phosphate group
(colored in black), forming MCD.
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blocks the access of NAD to its binding site (4). All of these
structural elements involved in XDH/XO conversion are
absent in mouse and human AOXs. This might explain the
preference of AOX toward oxygen as the final electron acceptor
(2).
The C-terminal 85-kDa domains of both AOXs and XORs
contain the Mo-MPT cofactor, which is the site of substrate
conversion. The substrate binds to the active site, and it is con-
verted into its product by an oxygen atom derived from water.
There are structural features along the substrate access funnel
that might account for the observed differences in substrate
specificities between AOX and XOR enzymes. In AOXs, the
funnel is wider and more anionic than in XORs. This implies
that AOXs are characterized by a better access of larger and
bulkier substrates as well as a broader substrate specificity. The
role exerted by specific amino acid residues of the active site in
the catalytic activity of mammalian AOXs has been elucidated
by site-directed mutagenesis studies performed with heterolo-
gous expression systems developed in E. coli (49 –53). The
active site of AOXs contains only a few highly conserved amino
residues (Glu1270, Phe923, Lys893, and Gln776; human AOX1
numbering), as many other residues are species-specific and
differ in the human and mouse enzymes (Fig. 4) (54). Glu1270 is
the essential residue for the catalytic activity of all the enzymes
belonging to the xanthine oxidase family (38).
The general reaction mechanism proposed for all AOXs is a
base-catalyzed mechanism starting with an initial attack of the
deprotonated Glu1270 to the -OH ligand of the Mo atom, result-
ing in the generation of a nucleophilic -O group (Fig. 4). Sub-
sequently, the activated Mo-O ligand attacks the substrate,
followed by a hydride transfer to the sulfido ligand, leading to
the generation of an intermediate species. In human AOX1, this
intermediate is stabilized by hydrogen-bonding interactions
with the Val811, Met889, and Lys893 residues of the active site.
This mechanism is supported by experimental evidence with
substituted N-heterocycles and by DFT calculations (55).
Whereas the lysine is also conserved in mammalian AOX
enzymes, the valine and methionine differ among AOX
enzymes, depending on their substrate specificity. The next
reaction step involves the release of the product from the
reduced Mo site and the binding of a water molecule. The reac-
tion cycle is completed once Mo is reoxidized and the two
reducing equivalents are transferred to molecular oxygen via
the two [2Fe-2S] clusters and FAD.
The evolution of AOX genes from bacteria to humans
The evolutionary history of AOX and XDH genes has been
reconstructed from the DNA-sequencing data available for
many organisms from bacteria to humans (11). A phylogenetic
analysis of the deduced protein sequences indicates that the
extant complement of mammalian AOX genes is likely to orig-
inate from two distinct and primordial gene duplication events
involving an ancestral XDH gene (24). The first duplication
involves a bacterial XDH gene and led to the development of the
current set of AOX genes observed in bacteria, protists, algae,
and plants (Fig. 5). The second duplication is likely to have
originated from a fish XDH gene, and it is at the basis of the
present complement of vertebrate AOX genes (Fig. 5).
Vertebrate AOX and XDH proteins are characterized not
only by high levels of similarity in terms of their amino acid
sequences, but also by a similar exon-intron organization of the
corresponding genes. As already mentioned, the mouse and rat
genomes contain four distinct loci, Aox1, Aox2, Aox3, and
Aox4, while a single active AOX1 gene is present in humans and
higher primates (Fig. 1). All mammalian AOX and XDH genes
consist of 35 and 36 exons, respectively. In mammals, the exon-
intron junctions of all of the AOX and XDH genes are strictly
conserved (10, 24). The Aox1, Aox2, Aox3, and Aox4 genes clus-
ter on a short region of mouse chromosome 1 and rat chromo-
some 9 in a head-to-tail configuration (Fig. 1). The presence of
Figure 4. The catalytic mechanism of human AOX1. Shown is a representation of the proposed reaction mechanism for human AOX1, as exemplified for the
substrate benzaldehyde. For details, see “Domain structure and catalytic mechanism of the AOX enzymes.”
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one or more AOX genes resulted from a process of asynchro-
nous AOX gene duplication events that occurred during the
evolution of vertebrates, starting from fishes (24). AOX1 is
likely to be the most ancient gene, whereas the order of appear-
ance of AOX3, AOX4, and AOX2 during vertebrate evolution is
still unknown. However, a number of considerations led to the
proposal that AOX4 is more ancient than AOX3, which, in
turn, appeared earlier than AOX2. It is concluded that the
presence of only a single AOX enzyme in humans is due to
gene deletion and pseudogenization events. In humans,
downstream of the AOX1 gene, the AOX4 gene has been
completely deleted, whereas the genes for AOX3 and AOX2
were transformed into inactive pseudogenes. Cows seem to
have maintained three active aldehyde oxidase genes (AOX1,
AOX4 and AOX2) on chromosome 2. The absence of nucle-
otide sequences with similarity to AOX3 strongly suggests
that this gene has been deleted. Deletion of the AOX3 gene
seems to be a conserved feature in horses; however, our pres-
ent view of the aldehyde oxidase cluster in this animal spe-
cies is still incomplete. Functional inactivation of AOX3
seems to be a common theme. The genome of dogs is char-
acterized by two seemingly active AOX4 and AOX2 loci and
two inactive AOX1 and AOX3 pseudogenes clustering on
chromosome 37. The vestiges of numerous exons with
nucleotide similarity to the rodent Aox1 and Aox3 genes are
easily identified on two separate regions slightly upstream of
the dog AOX4 and AOX2 loci. It is interesting to note that
the dog is currently the only mammalian species that seems
to be lacking AOX1, in addition to AOX3. Consequently, this
mammal is devoid of aldehyde oxidase activity in the liver.
Tissue-specific expression of different AOX enzymes
The only mammalian species extensively characterized for
the profiles of tissue- and cell-specific AOX expression are
humans and mice (2). The tissue-specific pattern of human
AOX1 mRNA expression, which is based on EST (expressed
sequence tag) data, is available in the UNIGENE section of the
NCBI site (UniGene Hs.406238). These data indicate that
detectable levels of the AOX1 transcript are observed in many
tissues. Adrenal glands, adipose tissue, and liver are the richest
sources of human AOX1, followed by the trachea, the glandular
epithelium of the prostate, bone, kidney, and connective tissue.
The presence of human AOX1 in the adrenal gland and glan-
dular epithelium of the prostate is consistent with a potential
role of the enzyme in steroid hormone metabolism.
In mice, the expression of the human AOX1 orthologous
gene (Aox1, UNIGENE Mm.26787) is more restricted, and it is
limited to a selected number of tissues (2). The largest amounts
of mAOX1 mRNA are present in the inner ear and the seminal
vesicles, although measurable amounts of the transcript are
observed also in the liver, the lung, and the central nervous
system (56). Expression of the mAox3 gene (UNIGENE
Mm.20108) is also relatively restricted, as significant amounts
of the corresponding transcript are found only in the liver, lung,
oviduct, and testis. Interestingly, mAOX3 and AOX1 are co-ex-
pressed in lung and liver. In liver, AOX3 is by far the most
abundant enzyme. Significant amounts of the mAOX4 tran-
script (UNIGENE Mm.244525) are evident in the fertilized
ovum, the inner ear, the tongue (2), and the epidermal layer of
the skin (57). However, the richest source of mAOX4 is the
Harderian gland, where the molybdo-enzyme accounts for
Figure 5. Phylogenetic tree of AOX and XDH proteins in prokaryotes and eukaryotes. The unrooted phylogenetic tree was generated from the available
prokaryotic as well as eukaryotic AOX and XDH protein sequences. The phylogenetic tree consists of all of the AOX and XDH proteins whose structure could be
predicted from the cloning of the corresponding cDNAs or deduced from genome-sequencing data.
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2% of all of the cytosolic proteins. The Harderian gland is a
large exocrine gland located behind the eye bulb and character-
ized by the secretion of a lipid-rich fluid, which lubricates the
eye surface and the fur (56). The most restricted profile of
expression is observed in the case of the mAOX2 enzyme (2), as
the corresponding transcript (UNIGENE Mm.414292) is
detectable only in the nasal cavity (58). In this location, high
levels of AOX2 mRNA are expressed in the Bowman’s gland of
the submucosal layer, which is responsible for the secretion of
the mucous fluid. Nevertheless, AOX2 is also detectable in the
sustentacular cells located in the apical layer of the nasal neu-
roepithelium. Given this localization, we speculate that AOX2
may play a role in the olfactory process.
Aox4 knockout mice give insights into the physiological
role of the enzyme
Further insights into the tissue-specific function of the vari-
ous mammalian AOXs have been and will be provided by the
generation of knockout animals. Currently, Aox4/ mice are
the only knockout animals available, whereas the construction
of knockouts in the other genes is in progress (59). Aox4/
mice are viable and fertile and generally do not show any major
morphological or behavioral abnormalities. Despite this,
Aox4/ mice are characterized by perturbations in the expres-
sion of clock genes, which are accompanied by reduced loco-
motor activity as well as resistance to diet-induced obesity and
hepatic steatosis. All of these effects are observed in both female
and male animals. Resistance to obesity is due to diminished fat
accumulation resulting from increased energy dissipation. The
phenomenon results from the white adipocytes of Aox4/
mice undergoing trans-differentiation toward thermogenic
brown adipocytes. The data obtained in this knockout model
indicate that AOX4 contributes to the local synthesis and bio-
disposition of endogenous retinoids in the Harderian gland and
skin, the principal sources of the AOX isoenzyme. The Hard-
erian gland’s transcriptome of Aox4/ mice shows an overall
down-regulation of direct retinoid-dependent genes as well as
perturbations in the pathways controlling lipid homeostasis
and cellular secretion, particularly in sexually immature ani-
mals. The skin of knockout mice is characterized by thickening
of the epidermis in basal conditions and after UV light expo-
sure. This is confirmed by analysis of the transcriptome, which
shows an enrichment and overall up-regulation of genes
involved in the process of epidermal thickening.
Metabolomic analyses performed in the Harderian glands of
Aox4/ and WT animals demonstrate the presence of 25
metabolites whose levels are significantly different in the two
types of mice. Among the differentially produced metabolites,
tryptophan and 5-hydroxyindolacetic acid stand out, because
they are part of the serotonin/melatonin biosynthetic pathway,
which controls circadian rhythms. Tryptophan is more abun-
dant in Aox4/ mice than WT mice, whereas 5-hydroxyin-
dolacetic acid is measurable only in Aox4/ mice. In addition,
the levels of serotonin are significantly lower in the Harderian
gland of Aox4/ than WT mice. A similar trend is observed in
the serum. Consistent with this, purified Harderian gland
AOX4 recognizes tryptophan and 5-hydroxyindolacetic acid,
but not serotonin, as substrates. Given the relevance of the tryp-
tophan/serotonin pathway for circadian rhythms and fat depo-
sition, the data support the idea that AOX4-dependent altera-
tions in the levels of tryptophan and 5-hydroxyindolacetic may
explain the perturbations in the two processes observed in
Aox4/ mice.
In conclusion, the phenotype of Aox4/ mouse provides
insights into the physiological function of AOX4, demonstrat-
ing that the enzyme plays a role in the control of diurnal
rhythms, adipogenesis, and locomotor activity, supporting a
link between these three processes. Interestingly, the reported
effects have no impact on life expectancy, which is the same in
Aox4/ and WT mice. It is possible that human AOX1 plays a
similar role as mAOX4 in adipogenesis, as there are data indi-
cating that the enzyme controls fat deposition in adipocyte cul-
tures (60). This point requires further investigations, as human
AOX1 may represent a useful molecular target for the develop-
ment of new anti-obesity agents.
Crystal structures of human AOX1 and mouse AOX3
To obtain further insights into differences of the four AOX
enzymes, and additionally to reveal substrate- and inhibitor-
binding sites, attempts have been made to solve the crystal
structures of the four enzymes from mice and AOX1 from
humans. So far, only the crystal structures of human AOX1 and
mAOX3 are available. However, our knowledge on the molec-
ular details of AOXs has greatly increased based on the 2.5 Å
(PDB: 4UHW) structure of human AOX1 in addition to a 2.6 Å
structure in complex with the substrate phthalazine and the
inhibitor thioridazine (PDB: 4UHX) (Fig. 6) (3). These enzymes
were purified after heterologous expression in E. coli. The crys-
tal structure of mAOX3 has been determined at 2.8 Å resolu-
tion (38, 50) (PDB: 3ZYV) from an enzyme that was directly
purified from mouse livers. Overall, human AOX1 and mAOX3
are characterized by a 65% amino acid sequence identity and
are very similar in terms of overall fold.
Details on substrate binding at the Mo active site were
obtained from the crystal structure of the phthalazine-thiorida-
zine complex cocrystallized with human AOX1 (Fig. 6) (3). The
structure is deemed to contain two putative gates controlling
access of the substrate and release of the product from the
Moco active site. Both gates correspond to mobile, unordered
regions, with Gate 1 consisting of the 652SFCFFTEAEK661 and
Gate 2 consisting of the 880LDESL884 amino acid sequences
(Fig. 7). By comparison, Gate 2 in mAOX3 and also in the more
distinctly related bovine XOR is remarkably ordered. In human
AOX1, Gate 1 is predominantly composed of bulky hydropho-
bic residues. With the exception of Glu660 (Asp in mAOX2),
Gate 1 amino acid residues are not conserved in other members
of the XOR family. In addition, Gate 1 is shorter in mouse
AOX2, AOX3, and AOX4. In all AOX enzymes, Asp881 of Gate
2 is strictly conserved, and it is always followed by another
acidic residue (Glu or Asp). The side chains of these amino
acids point toward the substrate channel and are likely to be
involved in binding or orienting polar substrates toward the
catalytic center. The active site of human AOX1 contains a few
residues (Glu1270, Phe923, Lys893, and Gln776) that are conserved
in all mammalian AOXs (Fig. 7). Glu1270 is a key residue present
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in all members of the xanthine oxidase family, whereas Lys893 is
specific to AOXs.
Substrate specificities of the mammalian AOX enzymes
Mouse AOX1, AOX3, AOX4, and AOX2 proteins are char-
acterized by 60% sequence similarity and show the same
domain and cofactor organization (2). To provide information
on differences in the substrate-binding regions and the funnels
leading to the active site, homology modeling based on the
available mAOX3 crystal structure (PDB: 3ZYV) has been per-
formed on mouse AOX1, AOX2, and AOX4 (54). The results
point to major differences among mouse AOX1, AOX2, AOX3,
and AOX4 in the substrate-binding region. On the basis of
these data, it has been proposed that the substrate-binding site
Figure 6. The crystal structure of the human AOX1 homodimer in complex with phthalazine (substrate) and thioridazine (inhibitor). The different
protein cofactors (FAD, FeSII, FeSI, and Moco) are indicated and are shown in a color-coded stick representation on the left monomer. The phthalazine substrate
as well as the substrate-binding site, including the flexible Gates 1 and 2, are marked in pink on the right monomer. The thioridazine-binding site is marked in
orange. The flexible loops at the FAD site (loop I and loop II) are marked in red (surface representation on the left monomer, cartoon representation on the right
monomer). The figure was generated using PDB entry 1UHW published by Coelho et al. (3).
Figure 7. The active site of hAOX1 and mAOX3. Shown are the residues of hAOX1 (left) and mAOX3 (right) surrounding the Moco and the location of Gate 1
and Gate 2 at the entrance of the substrate funnel. Missing residues in the electron density (and therefore not present in the coordinate files) are indicated by
thin lines. An amino acid sequence alignment of Gate 1 and Gate 2 of the human and mouse enzymes is given. The figure was created using PyMOL version 2.1.1.
JBC REVIEWS: Roles of multiple AOX enzymes in eukaryotes
J. Biol. Chem. (2020) 295(16) 5377–5389 5383











consists of a region that builds the inner active site consisting of
the amino acids Gln772, Ala807, Phe919, Phe1014, Lys889, and
Glu1266 (mAOX3 numbering) (Fig. 8). The more distal amino
acids in the substrate-binding tunnel are predicted to form an
enzyme-specific region, which shows remarkable differences in
the four mAOX enzymes. From these comparisons, mAOX1 is
proposed to have the widest substrate-binding funnel. Con-
versely, mAOX4 is proposed to have the narrowest funnel,
which is shaped by several bulky amino acid side chains. Mouse
AOX2 and AOX3 are proposed to contain funnels of similar
width, but with the mAOX2 funnel likely to be more hydropho-
bic (54).
To test whether the predicted substrate selectivity of the four
mouse AOX enzymes can be explained by the shape of the
entrance pocket, the kinetic parameters of the four mAOX
enzymes have been compared in a study using 30 different
structurally related aromatic and aliphatic substrates (61). In
this study, the 30 substrates considered were divided into azo-
heterocyclic compounds and molecules containing an aldehyde
group (benzaldehydes, alkyl aldehydes, and structurally related
cinnamaldehydes). As a general outcome, this study showed
that the three mouse AOX1, AOX2, and AOX3 enzymes have
no significant differences in substrate selectivity (61). Mouse
AOX1 and AOX3 are characterized by the highest catalytic
activities against the majority of the common substrates con-
sidered (a general summary of selected substrates is given in
Table 1) (61). Both mouse AOX1 and mouse AOX3 are mainly
expressed in the liver and have evolved overlapping substrate
specificities with high substrate turnover rates. It has to be
highlighted that AOX1 does not use N1-methylnicotinamide as
substrate. The mAOX3 enzyme thereby often is more effective
than mAOX1 under lower substrate concentrations (related to
a lower Km) (61). This role might be beneficial in the liver,
where most substrate degradation pathways occur. Thus,
mAOX1 and mAOX3 might cover different niches at different
substrate concentrations. The mAOX2 enzyme is also active
with all substrates tested; however, the enzyme is often more
effective under lower substrate concentrations (61). The role of
mAOX2 in rodents still needs to be elucidated in more detail in
the future. Expression of mAOX2 is highly restricted to the
Bowman’s gland in the nasal cavity, but no specific substrate for
mAOX2 has been identified. Overall, the substrate specificities
of mAOX2 are overlapping with those of mAOX1 and mAOX3.
Lower substrate concentrations might be present in the Bow-
man’s gland as compared with the liver, explaining the higher
catalytic efficiencies of the enzyme, and likely, high turnover
rates are also not mandatory in this tissue.
Conversely, mAOX4 is generally the least active enzyme with
the highest selectivity toward the substrates considered. In par-
ticular, mAOX4 is unable to use phenanthridine, N1-methylni-
cotinamide, ethylvanillin, and methoxybenzaldehyde as sub-
strates and is characterized by a poor reactivity toward purine,
whereas these compounds are generally good substrates for
most of the other three mouse AOX enzymes (Table 1). Con-
clusively, mAOX4 is unlikely to play an important role in the
oxidation of aromatic heterocyclic compounds. In addition and
consistent with the predicted hydrophobicity of the substrate-
binding funnel, mAOX4 does not recognize hydrophilic aro-
matic substrates and some N-heterocyclic compounds (54).
In conclusion, from the overlapping substrate specificities of
mouse AOX1, AOX2, and AOX3, similar substrate-binding
cavities were predicted according to modeling studies (54) (Fig.
8). The kinetic data show that only mAOX4 has a predicted
narrower substrate-binding funnel, suggesting a higher selec-
tivity, lower turnover numbers, and catalytic efficiencies for
most substrates tested (Table 1 and Fig. 8). In general, the sub-
strate selectivities predicted by only computationally based
analyses were not confirmed by kinetic data (54).
Figure 8. Active site and substrate binding funnel in mouse AOX enzymes. Representation of the substrate binding sites in mouse AOX1, AOX2, AOX3, and
AOX4 in addition to residues in the conserved and nonconserved substrate-binding funnel, which selects the substrate specificity. The representation of
mAOX3 is taken from the crystal structure (PDB: 3ZYV) (38), whereas those of mAOX1, mAOX2, and mAOX4 are taken from the modeled structures (54).
Residues in red indicate the amino acids whose nature is conserved in all mouse AOX enzymes; residues in blue are hydrophobic residues, partially conserved
and involved in substrate orientation; and residues in green are those specific for AOX4, with the AOX4-Met1088 residue highlighted in red. The funnel for mAOX4
is predicted to be smaller compared with the other enzymes.
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To identify the amino acids that are specific for the substrate
selectivity of mAOX4, site-directed mutagenesis was per-
formed. To this purpose, residues Val1016, Ile1018, and Met1088
in AOX4 (Fig. 8) were exchanged into the corresponding amino
acids present in the other mAOX enzymes. These residues are
not conserved and were identified to be specific for mAOX4
(61). The M1088T exchange had a major effect on the kinetic
constants of the AOX4 enzyme. The kcat of this variant was
increased with benzaldehyde, salicylaldehyde, phthalazine, and
pentanal compared with the corresponding value of WT coun-
terpart (61). Thus, this amino acid largely contributes to sub-
strate binding and turnover. Conclusively, whereas the role of
mAOX4 is specific to the Harderian gland, the enzyme appar-
ently has not evolved for high substrate turnover in this tissue,
because one selected amino acid exchange in an amino acid
specific for mAOX4 led to an increase in activity, whereas the
substrate selectivity was unaltered in this variant.
In general, the data discussed above indicate that there is an
urgent need to obtain the crystal structures of the three mouse
AOX enzymes (AOX1, AOX2, and AOX4), as this is the only
way to identify the structural differences at the basis of the
experimentally determined profiles of substrate selectivity. In
fact, computational modeling data seem to provide pieces of
information that are not sufficient to predict the substrate spec-
ificity of mouse AOX1, AOX2, AOX3, and AOX4.
The role of mammalian AOXs in the production of
reactive oxygen species
AOXs are cytosolic proteins and use molecular oxygen as the
sole electron acceptor. During substrate oxidation and molec-
ular oxygen reduction, AOXs generate mainly H2O2 in addition
to a proportion of O2
. radicals. So far, XOR in its XO form has
been considered to be the only molybdo-flavoenzyme involved
in the generation of O2
. (62–64). The fact that also AOXs pro-
duce a significant amount of O2
. radicals has been largely over-
looked in the past and might be of patho-physiological interest
(65). Particularly, it is noticeable that hepatic AOX1 is calcu-
lated to generate 24-fold larger amounts of O2
. than XOR. These
calculations are based on the relative levels of XO and AOX
enzymatic activity in human liver (17, 65). Thus, AOX1 and
other mammalian AOXs may represent significant sources of
ROS in the cytosol of liver and other tissues and may play a
critical role in ROS-mediated tissue injury under specific con-
ditions (66, 67). Given this background, the abilities of the puri-
fied mouse AOX1, AOX2, AOX3, and AOX4 enzymes to pro-
duce O2
. have been compared (53). The four mAOX enzymes
generally show a different rate of O2
. production in relation to
the amount of substrate converted. In particular, mAOX2 is the
most efficient producer of superoxide anions, with a rate of 40%
(Table 1). As the enzyme is located in the nasal mucosa, which
is one of the main sites of entrance for infective agents, it might
be feasible to speculate that mAOX2 produces ROS from
endogenous substrates to protect mice from viral and bacterial
infections. A similar role might be played by human and
mAOX1 in the liver. Also, mAOX1 was shown to produce a
ratio of 30% superoxide radicals, which is higher than the
reported value of 15–20% for XO (67). In contrast, mAOX3 and
mAOX4 produce a rate of 20% O2
. radicals per mole of substrate
converted, a ratio that is significantly lower as compared with
mAOX1 and mAOX2. In this and other tissues, it is also possi-
ble that AOX-dependent production of O2
. might be involved in
some of the toxic effects triggered by drugs and xenobiotics.
Potential physiological functions of mammalian AOXs in
endogenous pathways
The functional role of AOXs in the vertebrate organisms is
still largely unknown, although the broad substrate specificity
supports the idea that these enzymes are involved in numerous
metabolic pathways. In addition to the substrates shown in
Table 1, it has to be noted that under hypoxic conditions, AOXs
can also catalyze the reduction of N-oxides, sulfoxides, nitro-
compounds, and heterocycles (12, 68–71). More recently, it was
also demonstrated that AOXs hydrolyze amides (12, 72, 73).
Despite this, still very little information is available on the
endogenous substrates recognized by AOXs and the metabolic
pathways these enzymes are involved in.
Table 1
Substrate specificities of the mouse AOX enzymes
ND, not determined; , very good substrate (kcat  300 min1); , good substrate (kcat  120 –300 min1); , moderate substrate (kcat  50 –120 min1); ,
poor substrate (kcat  15–50 min1); , substrate not converted.
AOX1 AOX2 AOX3 AOX4
Former names AOX1 AOH3, AOX3L1 AOH1 AOH2
Potential functions ND ND ND Adipogenesis, circadian clock,
locomotor activity
Predominant expression in tissue Liver Bowman’s gland Liver Harderian gland
Rate of O2
. production in moles per mole of substrate 30% 40% 20% 20%
Preferred substrates/products: Aromatic aldehydes
Benzaldehyde3 benzoic acid    
Vanillin3 vanillic acid    
2-Methoxybenzaldehyde3 2-methoxybenzoic acid    
N-Heterocyclic compounds
Phthalazine3 phthalazinone    
Phenanthridine3 phenantridinone    
Purine3 hydroxypurine    
N1-Methylnicotinamide3 6-pyridone    
Cinnamaldehyde-related compounds
Cinnamaldehyde3 cinnamic acid    
4-Dimethylamino cinnamaldehyde3 4-dimethylamino cinnamic acid    
Aliphatic aldehyde
Hexanal3 hexanoic acid    
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As mentioned above, AOXs may play a role in tryptophan
metabolism, as metabolomic analyses conducted in Aox4
knockout mice demonstrated that tryptophan and 5-hydroxy-
indolacetic acid levels are higher in the Harderian gland of
genetically engineered than in that of control animals (62).
Nicotinamide catabolism is another metabolic pathway that
may be partially controlled by AOXs. In fact, AOXs oxidize
N1-methylnicotinamide into N1-methyl-2-pyridone-5-carbox-
amide and N1-methyl-4-pyridone-5-carboxamide. N1-Methyl-
nicotinamide is metabolized by AOX-enriched extracts ob-
tained from human (74), monkey (74), rat (75), rabbit (76), and
guinea pig liver (77), suggesting that the compound may be
recognized by human and other mammalian AOX1 isoenzymes
or mammalian AOX3. In this case, only purified mouse AOX3
and AOX2 proteins have been shown to recognize N1-methyl-
nicotinamide as a substrate (44).
AOXs are also suggested to be involved in vitamin A metab-
olism. In fact, AOXs are implicated in the oxidation of 9-cis-
and all-trans-retinal into the corresponding retinoic acids. All-
trans-retinoic acid is the active metabolite of vitamin A, and it
controls many aspects of vertebrate homeostasis in both the
developing and adult organisms. In vertebrate embryos, all-
trans-retinoic acid is a well-known morphogen, and it regulates
the development of numerous tissues and organs, including the
central nervous system. In adult organisms, the molecule influ-
ences numerous biological processes, including vision as well as
growth/differentiation of skin epithelial and hematopoietic
cells. At present, all-trans-retinal is the candidate endogenous
substrate of AOXs for which the greatest amount of supporting
evidence is available. Purified mouse liver AOX1 (78, 79) and
AOX3 (80), Harderian gland AOX4 (57), and nasal AOX2 (81)
proteins recognize retinaldehyde as a substrate. The data were
confirmed by using purified recombinant enzymes, which dem-
onstrates that mAOX1 is endowed with the highest retinalde-
hyde-metabolizing activity. In line with this, a marked decrease
in the levels of all-trans-retinoic acid is evident in the Harderian
gland and skin of Aox4 knockout mice relative to what is
observed in WT animals (57).
Roles in drug and xenobiotic metabolism
The presence of AOX1 and AOX1/AOX3 in the hepatic tis-
sue is the basis for the role played by this class of enzymes in the
metabolism of exogenous compounds, such as drugs and envi-
ronmental pollutants humans and other mammals are exposed
to (25, 38, 82). AOXs metabolize a variety of anti-tumor, immu-
nosuppressive, anti-malarial, and anti-viral drugs as well as
molecules acting in the central nervous system. As for the anti-
tumor and immunosuppressive agents, methotrexate and
6-mercaptopurine are two prominent examples of AOX sub-
strates. In the context of antimalarial and anti-viral drugs, liver
AOXs have been shown to oxidize cryptolepine into cryp-
tolepine-11-one (83) and quinine into 2-quinone (84).
AOXs metabolize not only drugs, but also molecules of tox-
icological interest, such as the environmental pollutants,
phthalazines, which are classical AOX substrates. Different
AOXs oxidize phthalazine into 1-hydroxyphthalazine, which
undergoes irreversible isomerization into 1-phthalazinone (3,
16, 85). Phthalazine administration increases rabbit liver AOX
activity, demonstrating that the compound is not only a sub-
strate, but it is also an AOX inducer (86). Two other examples of
relevant AOX substrates are caffeine (87) and the aromatic
aldehyde, vanillin. Vanillin is a sweetener, and it is oxidized into
the corresponding carboxylic acid by AOXs. Nitro-compounds
are further prototypes of toxic agents with the potential to be
metabolized by mammalian AOXs. Indeed, molecules contain-
ing a nitro functionality exemplify the ability of AOXs to act not
only as oxidases, but also as reductases (13, 71, 88–90). For
instance, various AOX isoenzymes have the potential to re-
duce 2-nitrofluorene, 1-nitropyrene, and 4-nitrobiphenyl,
three widespread pollutants, into the corresponding amines.
Interestingly, AOX-dependent reduction of these substrates is
observed not only in the liver (13), but also in the skin of mice
(88, 89). This has important ramifications for the human orga-
nism, as our skin contains AOX1 enzymatic activity (91), and
human AOX1-dependent reduction of nitro-compounds may
represent an important defense reaction against environmental
pollutants.
Conclusions
The role of human AOX1 in the metabolism of xenobiotics is
of general significance in drug development programs (20, 26,
27). However, the animal models used during preclinical stud-
ies represent a major problem, because unlike humans, some of
the most popular animal models, such as rodents, are charac-
terized by expression of other AOXs besides AOX1. Further,
dogs and cats are not good experimental tools for metabolic
studies involving human AOX1 substrates (27) because of inac-
tivation of the AOX1 and AOX3 genes by pseudogenization (24,
92). Thus, it is not surprising that canine studies have failed to
detect metabolites of AOX substrates either in vitro or in vivo
(93, 94).
The decrease in the number of active AOX isoenzymes from
rodents to humans is the result of progressive deletion/inacti-
vation of the corresponding genes. Combining the studies sum-
marized above, it is possible that, at least in part, the functions
carried out by rodent AOX1, AOX2, AOX3, and AOX4 are
combined in human AOX1, making it a multipurpose enzyme.
This may have resulted from evolutionary changes in the sub-
strate-binding funnel of human AOX1, which is wider and con-
sequently has resulted in an increase in the ability of the enzyme
to recognize physiological substrates originally specific to
AOX2, AOX3, and AOX4. However, a summary of the data
present in the literature mainly on the mouse enzymes implies
that AOX2 and AOX4 exert specialized functions in organs and
tissues that are no longer active or have become dispensable in
humans. The presence of two enzymes, mAOX1 and mAOX3,
in the liver might be beneficial to mice to cover a larger range of
substrate concentrations to be converted by the two enzymes.
More detailed future studies in addition to knockout mice in
each individual AOX enzyme are expected to provide more
information on the patho-physiological and tissue-specific
roles of these enzymes. In particular, the role of AOX4 in adi-
pogenesis, as revealed by the Aox4 knockout mouse, provides
important information that might be beneficial for the treat-
ment of obesity in humans.
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